Mirova Has $5.14 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Mirova lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 76.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 31,570 shares of the company’s stock after buying an additional 13,641 shares during the period. Mirova’s holdings in Zoetis were worth $5,144,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC increased its stake in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. grew its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 166 shares during the period. Murphy & Mullick Capital Management Corp acquired a new stake in shares of Zoetis in the 4th quarter valued at about $44,000. Asset Planning Inc bought a new stake in Zoetis in the 4th quarter valued at about $58,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in Zoetis during the 4th quarter worth approximately $59,000. Institutional investors own 92.80% of the company’s stock.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock valued at $312,254 in the last three months. Company insiders own 0.16% of the company’s stock.

Zoetis Trading Up 1.3 %

NYSE:ZTS opened at $148.64 on Friday. The firm has a market cap of $66.32 billion, a price-to-earnings ratio of 27.17, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm has a 50-day moving average price of $160.04 and a two-hundred day moving average price of $169.80. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.35%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ZTS shares. Morgan Stanley decreased their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Stifel Nicolaus decreased their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Finally, Piper Sandler raised their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $214.40.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.